Semax
ACTH Analogue — Neuro-Enhancement and Neuroprotection
Molecular Data
- Formula
- C37H51N9O10S
- Molecular Weight
- 813.92 g/mol
- Sequence
- Met-Glu-His-Phe-Pro-Gly-Pro
01
Overview
Semax is a heptapeptide analogue of ACTH(4-10) developed in Russia and used clinically there for stroke, cognitive impairment, and ADHD. As a nootropic, it is researched for its ability to increase BDNF (Brain-Derived Neurotrophic Factor), enhance memory consolidation, and provide neuroprotective effects following ischemic events.
02
Mechanism of Action
Semax activates melanocortin receptors and significantly increases BDNF and NGF expression in the hippocampus and cerebral cortex. It modulates dopaminergic, serotonergic, and cholinergic neurotransmission. Its influence on HIF-1α may confer protective effects under hypoxic conditions.
03
Research Highlights
Clinical use in Russia for ischemic stroke recovery and cognitive rehabilitation
Studies show 3-4x increase in BDNF levels following administration
Attention and reaction-time improvements demonstrated in healthy subject research
04
Dosage
Administration & Timing
Intranasal administration, 1–3 drops per nostril, 1–4× daily. Approved in Russia as a nootropic; timing independent of food.
Dosage Guidelines
Cycle Length
3–14 days acute; cycles of 2–4 weeks with equal rest in long-term research.
05
Reconstitution
Solvent
Sterile saline (0.9% NaCl) for intranasal formulation
Volume
Per manufacturer formulation (0.1–1% solution)
Concentration
0.1–1% aqueous solution
Storage
Refrigerate at 2–8 °C; protect from light. Discard 30 days after reconstitution.
Notes
Semax is a heptapeptide with poor oral bioavailability; intranasal is the standard research route. Store the nasal formulation upright and avoid contamination of the dropper.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
Semax is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
Semax Knowledge Graph
Explore how Semax connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
Semax — Common Research Questions
What is Semax?
Semax is a heptapeptide analogue of ACTH(4-10) developed in Russia and used clinically there for stroke, cognitive impairment, and ADHD. As a nootropic, it is researched for its ability to increase BD... Semax belongs to the Cognitive research category and is studied for its acth analogue — neuro-enhancement and neuroprotection.
How does Semax work?
Semax activates melanocortin receptors and significantly increases BDNF and NGF expression in the hippocampus and cerebral cortex. It modulates dopaminergic, serotonergic, and cholinergic neurotransmission. Its influence on HIF-1α may confer protective effects under hypoxic conditions.
What are the key research benefits of Semax?
BDNF and NGF upregulation for neuroplasticity. Cognitive performance and memory enhancement. Attention, focus, and executive function support. Neuroprotection following ischemic or hypoxic events. Anxiolytic properties without sedation. Mood stabilization and depression research.
What is the molecular structure of Semax?
Semax has the molecular formula C37H51N9O10S and a molecular weight of 813.92 g/mol. Its amino acid sequence is Met-Glu-His-Phe-Pro-Gly-Pro. This structural information is important for researchers studying receptor binding and pharmacokinetics.
What does the research say about Semax?
Clinical use in Russia for ischemic stroke recovery and cognitive rehabilitation Studies show 3-4x increase in BDNF levels following administration Attention and reaction-time improvements demonstrated in healthy subject research These findings are based on preclinical and clinical research. Semax is a research compound and these studies do not constitute medical advice.
Is Semax FDA approved?
No. Semax is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
What category does Semax belong to?
Semax belongs to the Cognitive category, which focuses on peptides investigated for their nootropic and neuroprotective potential, supporting mental clarity, memory consolidation, and neurological resilience. You can explore more compounds in this category on the Cognitive pillar page.
Related Articles
Semax: BDNF Upregulation and Cognitive Enhancement
A review of Semax's mechanism — from melanocortin receptor modulation to BDNF and NGF upregulation in the hippocampus.
Dihexa: Synaptogenesis and Spatial Memory
Washington State University research on Dihexa's dramatic effects on synaptogenesis and Morris water maze performance.
Noopept: The Dipeptide Nootropic
Understanding Noopept's prodrug conversion, BDNF/NGF upregulation, and its position as a dipeptide nootropic.
Scientific References
Asaad et al. — "Semax: cognitive and neuroprotective effects" (Front Pharmacol, 2022)
Kaplan et al. — BDNF and NGF upregulation, Mol Genet Mikrobiol, 1992
Clinical use in Russia for ischemic stroke rehabilitation
Clinical use in Russia for ischemic stroke recovery and cognitive rehabilitation
Studies show 3-4x increase in BDNF levels following administration
Attention and reaction-time improvements demonstrated in healthy subject research